Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2026 16:05 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Trevi Therapeutics to host conference call and webcast today, May 5, on 1Q 2026 financial results and business updates
April 30, 2026 16:05 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

Trevi Therapeutics announces oral presentation and multiple posters accepted for the ATS 2026 International Conference
April 23, 2026 16:05 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics to Participate in Upcoming May Events

NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
April 20, 2026 16:05 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
April 16, 2026 22:42 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
April 16, 2026 16:08 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
April 01, 2026 07:30 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics to Participate in Upcoming Events

Trevi Therapeutics to host an Investor and Analyst Day on May 7th in NYC and participate in key upcoming events.
March 10, 2026 16:05 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
March 09, 2026 07:30 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of...
March 02, 2026 07:30 ET | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics to Participate in Upcoming March Conferences

Trevi Therapeutics' senior management to participate in March investor conference and healthcare summit